Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther Natalie Olíva, Roberto Latagliata, Pierre Fenaux et al.|The Lancet Haematology|2017Cited by 163
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacyEsther Natalie Olíva, Maria Antonietta Aloe Spiriti, Roberto Latagliata et al.|Leukemia & lymphoma/Leukemia and lymphoma|2013Cited by 30
Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletionEsther N. Oliva, Roberto Latagliata, Maria Cuzzola et al.|European Journal Of Haematology|2010Cited by 29
Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependenceEsther Natalie Olíva, Roberto Latagliata, Michael Lauseker et al.|Cancer Medicine|2015Cited by 23
Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, TrialEsther Natalie Olíva, Roberto Latagliata, Valeria Santini et al.|Blood|2015Cited by 13